86189-69-7

Basic information

• Product Name: Felodipine
• Synonyms: 4-(2,3-DICHLOROPHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-3,5-PYRIDINECARBOXYLIC ACID METHYL ESTER;4-(2,3-DICHLOROPHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-3,5-PYRIDINEDICARBOXYLIC ACID METHYL ESTER;FLODIL;FELODAY;ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate;Felodipine;Agon sr;Brn 4331472
• CAS NO: 86189-69-7
• Molecular Formula: C18H19Cl2NO4
• Molecular Weight: 384.25
• Mol File: 86189-69-7.mol
• Article Data: 25

Chemical Properties

• Melting Point: 142-145℃
• Boiling Point: 471.5 °C at 760 mmHg
• Flash Point: 239 °C
• Appearance: light yellow/solid
• Density: 1.277 g/cm³
• Vapor Pressure: 4.62E-09mmHg at 25°C
• Refractive Index: 1.549
• Solubility: DMSO: 28 mg/mL
• Water Solubility: insoluble
• CAS DataBase Reference: Felodipine(CAS DataBase Reference)
• NIST Chemistry Reference: Felodipine(86189-69-7)
• EPA Substance Registry System: Felodipine(86189-69-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: S36:
• WGK Germany: 3
• RTECS: US7968700
• Hazardous Substances Data: 86189-69-7(Hazardous Substances Data)

Usage

Clinical Use

Calcium-channel blocker:HypertensionAngina

Drug interactions

Potentially hazardous interactions with other drugs Aminophylline and theophylline: possibly increased aminophylline and theophylline concentration. Anaesthetics: enhanced hypotensive effect. Antibacterials metabolism possibly inhibited by clarithromycin, erythromycin and telithromycin. Antidepressants: enhanced hypotensive effect with MAOIs. Antiepileptics: effect reduced by carbamazepine, barbiturates, phenytoin and primidone. Antifungals: metabolism inhibited by itraconazole and ketoconazole; negative inotropic effect possibly increased with itraconazole. Antihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect of postsynaptic alpha-blockers. Antivirals: concentration possibly increased by ritonavir; use with caution with telaprevir. Grapefruit juice: concentration increased - avoid concomitant use. Tacrolimus: possibly increased tacrolimus concentration

Metabolism

Felodipine is metabolised in the liver and all identified metabolites are devoid of vasodilating properties. Approximately 70% of a given dose is excreted as metabolites in the urine and about 10% with the faeces. Less than 0.5% of the dose is excreted unchanged in the urin

InChI:InChI=1/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3

Upstream product

• 626-34-6 ethyl 3-aminobut-2-enoate 
• 6334-18-5 2,3-dichlorobenzylaldehyde 
• 105-45-3 acetoacetic acid methyl ester 
• 175688-78-5 4-(2,3-Dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-(2-cyano-ethyl) ester 5-ethyl ester 
• 1352187-22-4 C₂₆H₂₇Cl₂NO₇S 
• 74-88-4 methyl iodide 
• 124-41-4 sodium methylate 
• 1215080-66-2 (R)-3-ethyl 5-((R)-1-hydroxy-3-(phenylthio)propan-2-yl) 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
• 1215080-64-0 (4S)-3-ethyl 5-(1-(phenylthio)-3-(tetrahydro-2H-pyran-2-yloxy)propan-2-yl) 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
• 1215080-63-9 (2R)-1-(phenylthio)-3-(tetrahydro-2H-pyran-2-yloxy)propan-2-yl 2-(2,3-dichlorobenzylidene)-3-oxobutanoate 
• 1215080-81-1 C₃₈H₄₂Cl₂N₂O₈S 
• 1215080-80-0 C₃₂H₃₃Cl₂NO₇S 
• 1352187-23-5 C₃₃H₃₄Cl₂N₂O₇S 
• 68064-69-7 (Z)-methyl 2-(2,3-dichlorobenzylidene)-3-oxobutanoate 

Relevant articles and documents

METHODS FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS

In one aspect the invention relates to a method of treatment selected from the group consisting of: (a) treating a symptom such as pain in a subject identified or diagnosed as having Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS); (b) treating a symptom such as pain in a subject having dysfunctional TRPM3 ion channel activity; (c) restoring NK cell function in a subject having dysfunctional TRPM3 ion channel activity; and (d) restoring calcium homeostasis in a subject having dysfunctional TRPM3 ion channel activity. The method comprises the step of administering to the subject a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of: (i) an opioid receptor antagonist; (ii) an opioid antagonist; and (iii) a therapeutic compound that restores TRPM3 ion channel activity. In some embodiments the therapeutic compound is naltrexone hydrochloride.

Evaluation of the chiral recognition properties and the column performances of three chiral stationary phases based on cellulose for the enantioseparation of six dihydropyridines by high-performance liquid chromatography

Separations of six dihydropyridine enantiomers on three commercially available cellulose-based chiral stationary phases (Chiralcel OD-RH, Chiralpak IB, and Chiralpak IC) were evaluated with high-performance liquid chromatography (HPLC). The best enantioseparation of the six chiral drugs was obtained with a Chiralpak IC (250?×?4.6?mm i.d., 5?μm) column. Then the influence of the mobile phase including an alcohol-modifying agent and alkaline additive on the enantioseparation were investigated and optimized. The optimal mobile phase conditions and maximum resolution for every analyte were as follows respectively: n-hexane/isopropanol (85:15, v/v) for nimodipine (R?=?5.80) and cinildilpine (R?=?5.65); n-hexane/isopropanol (92:8, v/v) for nicardipine (R?=?1.76) and nisoldipine (R?=?1.92); and n-hexane/isopropanol/ethanol (97:2:1, v/v/v) for felodipine (R?=?1.84) and lercanidipine (R?=?1.47). Relative separation mechanisms are discussed based on the separation results, and indicate that the achiral parts in the analytes' structure showed an important influence on the separation of the chiral column.

Metal-free-mediated oxidation aromatization of 1,4-dihydropyridines to pyridines using visible light and air

A metal-free and environmentally friendly aerobic aromatization photosensitized by organic dye eosin Y bis(tetrabutyl ammonium salt) (TBA-eosinY) has been developed. With the aid of K2CO3, the aerobic catalytic system converts 1,4-dihydropyridines to their corresponding pyridine derivatives efficiently under visible light irradiation (λ=450 nm) at room temperature.